Kathy R.

Kathy R. has held various roles in the pharmaceutical industry since 2003. Kathy began their career at GlaxoSmithKline (GSK) as Vice President and Head of Biopharmaceutical Development. Kathy then moved on to become Vice President and Medicine Development Leadership of Azrerra/ofatumumab, Head of Oncology Clinical Operations, and Vice President and Project Leader of the MIGU Medicine Development Center. In 2013, they became Senior Vice President and Head of R&D at Stiefel, a GSK company. In 2016, they were appointed Senior Vice President and Head of Projects, Clinical Platforms and Sciences (PCPS) at GSK. Since 2018, they have been a Non Executive Director at Navidea Biopharmaceuticals Inc. and Viking Therapeutics, Inc., and in 2020 they took on the same role at Code Biotherapeutics.

Kathy R. obtained their PhD in Pharmaceutical Sciences from the University of Rhode Island between 1984 and 1988. Prior to that, they obtained their Bachelor of Pharmacy (B.Pharm.) from the University of London between 1980 and 1983, qualifying their as a UK Registered Pharmacist.